Navigation Links
Studies suggest HIV subtype more deadly than others
Date:11/27/2007

Two studies led by researchers at the Johns Hopkins Bloomberg School of Public Health found that people infected with HIV in Thailand die from the disease significantly sooner than those with HIV living in other parts of the world. According to the researchers, the shorter survival time measured in the studies suggests that HIV subtype E, which is the most common HIV subtype in Thailand, may be more virulent than other subtypes of the virus. Both studies are published in a special issue of the journal AIDS.

The first study followed 228 men over a 14-year period starting in 1991. All of the men were serving in the Thai military and were HIV-negative when they enrolled in the study. The researchers tested for HIV every six months to determine approximately when they acquired HIV. The men were also diagnosed at a time before combination antiretroviral drug therapy was available.

The researchers compared the group of Thai men to a group of similar HIV-positive men living in North America and Europe who were included in another study. The median time from HIV infection to death for the Thai men was 7.8 years compared to 11 years for HIV-positive men living in North America and Europe. The survival rate for the Thai men was also lower than studies of similar populations living in low- and middle-income countries in sub-Saharan Africa where subtypes A, C, D and G circulate. However, the shorter survival after HIV infection among persons in Africa infected with subtype D was similar to the survival among the Thai men.

We were surprised to learn that the young military recruits from Thailand appeared to develop AIDS more quickly and have shorter survival after their HIV infection than persons in Africa who were carefully followed, said lead author Ram Rangsin, assistant professor of Community and Military Medicine at Phramongkutklao College of Medicine in Bangkok. Rangsin conducted the research while studying at the Bloomberg School of Public Health. Fortunately, the men who have survived after their infection are now receiving treatment with effective antiviral drugs and doing very well.

For the second study, researchers followed a small group of male blood donors and their wives from 1992 to 2007. All of the men and women were determined to have acquired HIV fewer than two years prior to enrolling in the study. The median survival rate from infection to death was 7.8 years for the men and 9.6 years for the women. Again, the survival rate was lower than the 11 years reported for HIV-positive men in developed countries.

The fact that both young military conscripts and blood donors and their wives in Thailand had similarly shortened survival compared to persons in the U.S. and Africaexcept those infected with subtype D virusessuggests that viral subtypes D and E may be more virulent than many other viral subtypes, said Kenrad E. Nelson, MD, a senior author of both studies and professor in the departments of Epidemiology and International Health at the Bloomberg School. If we could understand better the virulence characteristics of these viruses, we might learn something more about why those with HIV infection progress to AIDS, usually many years after they are infected.

The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up was written by Ram Rangsin, Phunlerd Piyaraj, Thira Sirisanthana, Narongrid Sirisopana, Onsri Short and Kenrad E. Nelson.


'/>"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
5. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
6. Studies Prove Exercise Can Heal the Body Mind and Soul
7. Studies Shed New Light on Breast Cancer, Treatment
8. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
9. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... host, Swirl, A Wine Tasting Event at the La Gorce Country Club in ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology: